[1]李杨,刘文杰,郭莉.外周血CD59，LGR5 和CK7 水平表达对宫颈癌前病变进展风险的预测价值研究[J].现代检验医学杂志,2023,38(05):105-109+126.[doi:10.3969/j.issn.1671-7414.2023.05.020]
　LI Yang,LIU Wenjie,GUO Li.Predictive Value of Combined Detection of Peripheral Blood CD59, LGR5 and CK7 on the Risk of Progression of Cervical Precancerous Lesions[J].Journal of Modern Laboratory Medicine,2023,38(05):105-109+126.[doi:10.3969/j.issn.1671-7414.2023.05.020]
点击复制

外周血CD59，LGR5 和CK7 水平表达对宫颈癌前病变进展风险的预测价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
105-109+126
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Predictive Value of Combined Detection of Peripheral Blood CD59, LGR5 and CK7 on the Risk of Progression of Cervical Precancerous Lesions
文章编号:
1671-7414（2023）05-105-06
作者:
李杨; 刘文杰; 郭莉
（西北大学附属医院/ 西安市第三医院妇产科，西安 710016）
Author(s):
LI Yang; LIU Wenjie; GUO Li
（Department of Gynaecology and Obstetrics, the Third Hospital of Xi’an/Affiliated Hospital of Northwest University, Xi’an 710016, China）
关键词:
癌前病变; 宫颈癌; CD59; 血富含亮氨酸重复序列的G 蛋白偶联受体5; 细胞角蛋白7
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.05.020
文献标志码:
A
摘要:
目的 探讨联合检测外周血CD59，血富含亮氨酸重复序列的G 蛋白偶联受体5（leucine-repeat-rich G-proteincoupled receptor 5，LGR5）和细胞角蛋白7（cytokeratin 7，CK7）对宫颈癌前病变进展风险的预测价值。方法 回顾性分析2019 年1 月～ 2022 年1 月西安市第三医院收治的342 例宫颈癌前病变患者的临床资料，根据病情进展情况分为宫颈上皮内瘤变（cervical intraepithelial neoplasias, CIN）Ⅰ组（n=89），CIN Ⅱ组（n=128），CIN Ⅲ组（n=65）和宫颈癌组（n=60）。统计四组一般资料，CD59，LGR5 和CK7，Logistic 回归方程分析癌前病变进展至宫颈癌影响因素，绘制决策分析（decision curve analysis，DCA）曲线分析CD59，LGR5 和CK7 联合临床获益度，绘制临床影响曲线（clinicalimpact curve，CIC）分析在各个阈概率下，CD59，LGR5 和CK7 联合预测价值与实际情况符合度。结果 宫颈癌组、CIN Ⅲ组、CIN Ⅱ组和CIN Ⅰ组患者HPV 感染率（50.00%，7.70%，1.56%，0.00%）及外周血CD59 蛋白（55.35%±6.38%，46.17%±5.12%，42.24%±4.13%，38.35%±4.02%），LGR5 基因（0.91±0.25，0.38±0.08，0.25±0.06，0.15±0.04），CK7 基因（10.12±3.04，7.96±1.55，7.12±1.48，6.50±1.36）表达水平比较，宫颈癌组＞ CIN Ⅲ组＞ CIN Ⅱ组＞CIN Ⅰ组，差异具有统计学意义（χ2=118.290，F=165.265，567.350，51.982，均P ＜ 0.05）；Logistic 回归显示，CD59（OR：3.483，95%CI：1.614 ～ 7.518），LGR5（OR：5.241，95%CI：2.689 ～ 10.214），CK7（OR：4.078，95%CI：1.461 ～ 11.742）水平是癌前病变患者进展至宫颈癌的高危因素（P ＜ 0.05）；DCA 曲线显示，在0.1 ～ 0.45 范围内，LGR5，CK7 和CD59 联合应用具有更高临床获益度；CIC 曲线显示，横轴从0.4 后，LGR5，CK7 和CD59 联合预测价值与实际情况具有较高的符合率。结论 LGR5，CK7 和CD59 是影响癌前病变进展至宫颈癌高危因素，三者联合或可成为预测患者临床获益有效方案，有利于减少宫颈癌发生，增加患者净获益。
Abstract:
Objective To investigate the predictive value of the combined detection of peripheral blood CD59, blood leucinerepeat- rich G protein-coupled receptor 5 (LGR5), and cytokeratin 7 (CK7) on the risk of cervical precancer progression. Methods The clinical data of 342 patients with precancerous lesions in the Third Hospital of Xi’an from January 2019 to January 2022 were retrospectively collected, and they were divided into cervical intraepithelial neoplasia (CIN) I group (n=89), CIN II group (n=128) and CIN III group (n=89) according to their disease progression, and cervical cancer group (n=60). The general data, CD59, LGR5 and CK7 of the four groups were collected. Logistic regression equations were used to analyze the influencing factors of the progression of precancerous lesions to cervical cancer, draw a decision curve analysis (DCA) to analyze the combined clinical benefits of CD59, LGR5, and CK7, draw a clinical impact curve (CIC) to analyze the consistency between the combined predictive value of CD59, LGR5, and CK7, and the actual situation at various threshold probabilities. Results HPV infection rate (50.00%, 7.70%, 1.56%, 0.00%), peripheral blood CD59 molecule(55.35%±6.38%，46.17%±5.12%，42.24%±4.13%， 38.35%±4.02%), LGR5 (0.91±0.25, 0.38±0.08, 0.25±0.06, 0.15±0.04), and CK7 gene (10.12±3.04, 7.96±1.55, 7.12±1.48, 6.50±1.36) expression levels were compared in the cervical cancer group > CIN III group > CIN II group > CIN I group, and the differences were statistically significant (χ2=118.290, F=165.265, 567.350, 51.982, all P<0.05). Logistic regression showed that CD59 (OR: 3.483, 95% CI: 1.614 ～ 7.518), LGR5 (OR: 5.241, 95% CI: 2.689 ～ 10.214), and CK7 (OR: 4.078,95% CI: 1.461 ～ 11.742) levels were high risk factors for progression to cervical cancer in patients with precancerous lesions factor (P<0.05). The DCA curve showed that in the range of 0.1 to 0.45, the combination of LGR5, CK7 and CD59 had a higher clinical benefit. The CIC curve showed that after the horizontal axis changes from 0.4, the joint prediction value of LGR5, CK7 and CD59 has a high coincidence rate with the actual situation. Conclusion LGR5, CK7 and CD59 are high-risk factors affecting the progression of precancerous lesions to cervical cancer. The combination of the three may be an effective solution to predict the clinical benefit of patients, which is beneficial to reduce the occurrence of cervical cancer and increase the net benefit of patients.

参考文献/References:

[1] 张治洋, 李功娟. 10 株宫颈癌细胞系中MALAT1 的表达及其对顺铂敏感性的影响[J]. 现代检验医学杂志, 2021, 36(5):110-113, 188. ZHANG Zhiyang, LI Gongjuan. Expression of MALAT1 in 10 cervical cancer cell lines and its effect on cisplatin sensitivity[J]. Journal of Modern Laboratory Medicine, 2021, 36(5): 110-113, 188.
[2] NAVALLAS M, DANEMAN A, AMIRABADI A, et al. Utility of sonography for identifying metastatic cervical adenopathy in children with differentiated thyroid carcinoma at presentation[J]. Pediatric Radiology, 2021, 51(2): 273-281.
[3] BOUVARD V, WENTZENSEN N, MACKIE A, et al. The IARC perspective on cervical cancer screening[J].New England Journal of Medicine, 2021, 385(20): 1908-1918.
[4] WU Yuzhong, L? Mengmeng, QIAN Tianye, et al. Correlation analysis of Ki67 and CK7 expression with clinical characteristics and prognosis of postoperative cervical adenocarcinoma patients[J]. Annals of Palliative Medicine, 2021, 10(9): 9544-9552.
[5] ZHANG Ronghua, LIU Qiaofei, PENG Junya, et al. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by upregulation of CD59[J]. Cell Death Dis, 2019, 10(11): 836.
[6] ABDEL-LATIF M, SAIDAN Suzan, MORSY B M. Coenzyme Q10 attenuates rat hepatocarcinogenesis via the reduction of CD59 expression and phospholipase D activity[J]. Cell Biochemistry and Function, 2020, 38(4): 490-499.
[7] IQBAL M A, WANG Xian, ZHANG Guoliang ,et al. A comparison of the efficiency of diagnostic ultrasound and magnetic resonance imaging of cervical lymph nodes in papillary thyroid carcinoma[J]. Journal of X-Ray Science and Technology, 2021, 29(6)：1033-1044.
[8] 蔡钰, 杨树环, 姚红, 等. 宫颈癌患者外周血LGR5水平与肿瘤增殖、侵袭基因表达的相关性[J]. 中国性科学, 2022, 31(3): 50-54. CAI Yu, YANG Shuhuan, YAO Hong, et al. The correlation between the level of LGR5 in peripheral blood of patients with cervical cancer,tumor proliferation and invasion genes expression[J]. Chinese Journal of Human Sexuality, 2022, 31(3): 50-54.
[9] 葛美玲. Wnt-1,β-catenin, Lgr5 在宫颈癌中的表达及意义[D]. 青岛：青岛大学, 2019. GE Meiling. Expression and significance of Wnt-1, beta-catenin and LGR5 in cervical cancer[D]. Qingdao: Qingdao University, 2019.
[10] NOVELLASDEMUNT L, KUCHARSKA A, JAMIESON C, et al. NEDD4 and NEDD4L regulate Wnt signalling and intestinal stem cell priming by degrading LGR5 receptor[J]. EMBO Journal, 2020, 39(3): e102771.
[11] 张琳. Nanog, LGR5 在宫颈癌中的表达及其临床意义[D]. 青岛：青岛大学, 2018. ZHANG Lin. The expression and the clinical significance of Nanog and LGR5 in cervical carcinoma[D]. Qingdao: Qingdao University, 2018.
[12] MARU Y, KAWATA A, TAGUCHI A , et al . Establishment and molecular phenotyping of organoids from the squamocolumnar junction region of the uterine cervix[J]. Cancers, 2020, 12(3): 694.
[13] 许玉, 程忠平. 基于类器官模型的宫颈癌铂类化疗药物敏感性的免疫组化指标分析与探索[J]. 同济大学学报( 医学版), 2021, 42(1): 68-73. XU Yu , CHENG Zhongping. Analysis of chemosensitivity of cervical cancer to platinum drugs by immunohistochemical indices based on organoid model [J]. Journal of Tongji University(Medical Science), 2021, 42(1): 68-73.
[14] 康敏, 邢益祥, 赵铁, 等. CK7 HMGA1 在宫颈上皮内病变和宫颈癌诊断中的价值[J]. 解剖学研究,2022, 44(1): 24-28. KANG Min, XING Yixiang, ZHAO Tie, et al. The value of CK7 HMGA1 in the diagnosis of cervical intraepithelial lesions and cervical cancer[J]. Anatomy Research, 2022, 44(1): 24-28.
[15] REGAUER S, REICH O, KASHOFER K. HPVnegative squamous cell carcinomas of the cervix with special focus on intraepithelial precursor lesions[J].American Journal of Surgical Pathology, 2022, 46(2): 147-158.
[16] 田小丽, 高利昆, 何惠华, 等. 原发性宫颈透明细胞腺癌合并宫颈子宫内膜异位症临床病理观察[J]. 诊断病理学杂志, 2021, 28(5): 357-361. TIAN Xiaoli, GAO Likun, HE Huihua, et al. Clinicopathological features of primary cervical clear cell adenocarcinoma with cervical endometriosis[J].Chinese Journal of Diagnostic Pathology, 2021, 28(5): 357-361.
[17] SON S W, CHO E, CHO H, et al. NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59[J]. Scientific Reports, 2022, 12(1): 8652.
[18] WANG Li, LIANG Tingting. CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells[J]. AMB Express, 2020, 10(1): 54.
[19] QIN Yating, FENG Yusheng, MA Yaojia, et al. Tumorsensitive biodegradable nanoparticles of molecularly imprinted polymer-stabilized fluorescent zeolitic imidazolate framework-8 for targeted imaging and drug delivery[J]. ACS Applied Materials & Interfaces, 2020, 12(22): 24585-24598.
[20] 张彬彬, 刘晶晶, 李丹, 等. 宫颈癌组织STING,CCL22, IDO 表达变化及其临床意义[J]. 山东医药,2020, 60（7）：11-15. ZHANG Binbin, LIU Jingjing, LI Dan, et al. Expression changes of Sting, CCL22 and IDO in cervical cancer and its clinical significance[J]. Shandong Medical Journal, 2020, 60(7): 11-15.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
　TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
　GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
　CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周　静,李　智,周　玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
　ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(05):24.[doi:10.3969 ／ j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王　纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6，p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
　XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]高红敏,杨红英,刘　鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
　GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):85.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
[7]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a，miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
　ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[8]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
　ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[9]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
　HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(05):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[10]方　芳,吴　玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
　FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]

备注/Memo

备注/Memo:
基金项目：陕西省医学科学研究课题计划（2019JM1844）：外周血CD59，LGR5，CK7 在癌前病变进展至宫颈癌的预测价值研究。
作者简介：李杨（1986-），女，临床医学本科，主治医师，研究方向：妇科临床。
通讯作者：郭莉（1988-），女，主治医师，研究方向：中西医结合妇科，E-mail：11078937359@qq.com。
更新日期/Last Update: 2023-09-15